Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The company expects that this development could improve the strength of its application to the FDA for new drug approval
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Investment is additive to KKR’s existing health care growth strategy
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Subscribe To Our Newsletter & Stay Updated
